Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Ester doai
Reexamination Certificate
2007-12-25
2007-12-25
Tucker, Zachary C (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Ester doai
Reexamination Certificate
active
11043697
ABSTRACT:
The present invention relates to compounds and pharmaceutical compositions which are proteonaimetic and to methods for inhibiting the interaction of an alpha-helical protein with another protein or binding site. Methods for treating diseases or conditions which are modulated through interactions between alpha helical proteins and their binding sites are other aspects of the invention. In particular, the invention relates to treatment of viral infections using terphenyl derivatives.
REFERENCES:
patent: 4701459 (1987-10-01), Meanwell et al.
patent: 6858600 (2005-02-01), Hamilton et al.
patent: 0 933 346 (1999-08-01), None
patent: 2 687 668 (1993-08-01), None
patent: 1 379 785 (1975-01-01), None
patent: WO 9804508 (1998-02-01), None
patent: WO 98/16503 (1998-04-01), None
Million et al, “Inhibition of the EGF-Stimulated Cellular Proliferation of ER 22 Cells by Hydroxybiphenyl Derivatives” Journal of Medicinal Chemistry, vol. 38(23), pp. 4693-4703 (1995).
Nair, P. “Epidermal Growth Factor Receptor Family and its Role in Cancer Progression” Current Science, vol. 88(6), pp. 890-898 (Mar. 6, 2005).
Angew. Chem. Int. Ed. 2002, vol. 41, pp. 278-281, 2002, Justin T. Ernst, Olaf Kutzki, Asim K. Debnath, Shibo Jiang, Hong Lu, and Andrew D. Hamilton.
American Chemical Society, vol. 123, No. 22, pp. 5382-5383, May 11, 2001, Brendan P, Orner, Justin T. Ernst, and Andrew Hamilton.
Agrawai and Aikhatib, Chemokine receptors: emerging opportunities for new anti-HIV therapies. Expert Opin. Ther. Targets, 5(3):303-326 (2001).
CAPLUS, DN 122:128607, also cited as Yoshida et al., Chemical & Pharmaceutical Bull., 39/5, 1157-62 (1991), Abstract.
CAPLUS DN 108: 131815, also cited as U.S.P. 4701459, CAS RN113260-0108, Abstract.
Cecil Textbook of Medicine, Simone, “Oncology”, Part XIV, vol. 1, 20thEdition, p. 1004-1010 (1996).
Cecil Textbook of Medicine, Damasio, A.R., “Alzheimer's Disease and Related Dementias”, Part 400, vol. 2, 20thEdition, p. 1992-1996 (1996).
Cheng, et al., Local helix content and RNA-binding activity of the N-terminal leucine-repeat region of hepatitis delta antigen, J Biomolecular MNR, 12:183-188, (1998).
Coyle et al., Alzheimer's Disease: A Disorder of Cortical Cholinergic Innervation. Science, vol. 219, pp. 1164-1168, (1983).
Debnath et al., Structure-based Identification of Small Molecule Antiviral Compounds Targeted to the gp41 Core Structure of the Hyman Immunodeficiency Virus Type 1, J. Med. Chem. 42:3203-3209, (1999).
Hong, et al., Identification of a Minimal Hydrophobic Domain in the Herpes Simplex Virus Type 1 Scaffolding Protein Which Is Required for Interaction with the Major Capsid Protein, J. Virology, Jan. pp. 533-540 (1996).
Liu and Jiang, High Throughput Screening and Characterization of HIV-1 Entry Inhibitors Targeting gp41: Theories and Techniques, Current Pharmaceutical Design, 10:1827-1843 (2004).
Lou, et al., Solution Structure of an N-Capping Peptide from the N-terminal Leucine-Repeat Region of Hepatitis Delta Antigen, Archives of Biochemistry and Biophysics, 337:219-227, (2000).
Offensperger, et al., Molecular therapeutic strategies in hepatitis B virus infection, Clin. Investig 72:737-741 (1994).
Root, et al., Protein Design of an HIV-1 Entry Inhibitor, Science, 291:884-888, (2001).
Tagat et al., Piperazine-Based CCR5 Antagonists as HIV-1 Inhibitors. I: 2(S)-Methyl Piperazine as a Key Pharmacophore Element, Biorganic & Medicinal Chemistry Letters, 11:2143-2146, (2001).
Uckun et al., Structure-Based Design of Novel Anticancer Agents, Current Cancer Drug Targets, 1:59-71, (2001).
Verani and Lusso, Chemokines as natural HIV antagonists, Curr Mol Med 2(8):691-702 (2002) (abstract).
Walters, et al., Mutation of Single Hydrophobic Residue I27, L35, F39, L58, L65, L67, or L71 in the N Terminus of VP5 Abolishes Interaction with the Scaffold Protein and Prevents Closure of Herpes Simplex Virus Type 1 Capsid Shells, Journal of Virology, 77(7):4043-4059, (2003).
Dehne et al. “Synthesis of liquid-crystalline 4,4”-bis(organo)-p-terphenyls. XP008055286, Z.Chem, 9(11):423-424, 1969.
Kobayashi et al, “Palladium complex-catalyzed carboalkoxylation of bis(chloromethyl)arenas.” Journal of Molecular Catalysis, 45:91-109, 1988.
Brand et al., “Functionalized hexa-peri-hexabenzocoronenes: Stable supramolecular order by polymerization in the discotic mesophase.” Chem. Mater., 12: 1638-1647, 2000.
Ernst Justin
Hamilton Andrew D.
Orner Brendan
Coleman Henry D.
Sapone William J.
Sudol R. Neil
Tucker Zachary C
Yale University
LandOfFree
Proteomimetic compounds and methods does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Proteomimetic compounds and methods, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Proteomimetic compounds and methods will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3862646